2022 cohort company Echo IQ has partnered with Cassling, a company that will act as a sales agent for Echo IQ’s EchoSolv software. EchoSolv is a proprietary artificial intelligence clinical decision support platform that supports cardiology practitioners in diagnosing structural heart disease. Read more here.
Tracy Warren, CEO of 2020 cohort company Astarte Medical and a former venture investor, talks the best data, the pace of tech innovation, curbing the all-time high in premature births, and best practices to prevent lapses and errors in the neonatal intensive care unit. Read more here.
2022 cohort company Acorai has been accepted to the Cedars-Sinai Accelerator. Acorai develops a device for heart failure management through noninvasive intracardiac pressure monitoring to help reduce hospitalizations and readmissions. Read more here.
2020 cohort company Astarte, a clinical intelligence company focused on protocol-driven pediatric care, has partnered with Virginia-based Carilion Children’s Hospital to coordinate care within its neonatal intensive care unit. Read more here.
2022 cohort company Echo IQ has its first sale of the company’s EchoSolv™ diagnostic software for aortic stenosis identification to an Australian hospital. Read more here.
2022 cohort company Acorai announced that the U.S. FDA has granted Breakthrough Device Designation for Acorai's Heart Monitor, a device for the non-invasive estimation of diastolic pulmonary artery pressure (dPAP), systolic pulmonary artery pressure (sPAP), and mean pulmonary artery pressure (mPAP) in patients with Stage C Heart Failure who have been referred for hemodynamic monitoring. Read more here.
2022 cohort company Acorai announced the initiation of a global clinical trial with the enrollment of its first patient in London, UK. Read more here.
2022 cohort company Mediwhale Inc. developed Reti-CKD, a predictive risk score for CKD, the first comprehensive AI diagnostic solution for CKD using retinal imaging. The process takes about 30 seconds and involves a retinal scan with color fundus imaging. Read more here.
2022 cohort company Echo IQ has announced plans to release six new cardiac decision-support solutions, significantly expanding its EchoSolv cardiology platform between November 2023 and January 2024. Read more here.
2020 cohort company Astarte, a clinical intelligence company focused on protocol-driven pediatric care, has been busy adjusting its digital health platform to provide more assistance with monitoring and alerting medical staff to the patients who face specific risks. Read more here.
2020 cohort company Vena Vitals is a winner of Orange County’s 2023 Pitch. Launch. Grow. competition and will be awarded a 1-year sponsored lab bench at University Lab Partners, the premier wet lab incubator in Irvine, California. Read more here.
2018 cohort company Lapovations has been awarded a $500K Phase IIB Small Business Innovation Research (SBIR) matching grant from the National Science Foundation (NSF). Read more here.
2018 cohort company Day Zero Diagnostics has completed a $16M round of financing. This latest financing brings the total raised by Day Zero Diagnostics to $49M in venture capital funding and over $18M in non-dilutive funding. Read more here.
2020 cohort company Astarte, is forming a joint venture with Tiny Health, makers of gut microbiome tests for babies and expecting parents. The partners have agreed to develop a clinical-facing technology solution to support gut health for preterm and critically ill infants receiving care in the neonatal ICU. Read more here.